{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:efferon-q137943996-answer-0a0debd153c0a2564ffe","key":"buyer_question:efferon-q137943996-answer-0a0debd153c0a2564ffe","kind":"buyer_question","slug":"efferon-q137943996-answer-0a0debd153c0a2564ffe","canonicalUrl":"https://directory.readyscan.ai/corpus/buyer-question/efferon-q137943996-answer-0a0debd153c0a2564ffe","machineUrl":"https://directory.readyscan.ai/discovery/corpus/buyer-question/efferon-q137943996-answer-0a0debd153c0a2564ffe.json","datePublished":"2026-10-24","dateModified":"2026-10-24","materialFingerprint":"fnv1a64:7da53b110e3b8ada","membershipFingerprint":"fnv1a64:3569d99e4e983d6c","relatedEntitySlugs":["efferon-q137943996"],"relatedSurfaceKeys":["buyer_question:efferon-q137943996-answer-6539a10d54fcbd916be7","buyer_question:efferon-q137943996-answer-cb22df4ff4ac8bb01c5f","evidence:efferon-q137943996"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"efferon-q137943996-content-d4e31da64907be66-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q137943996","sourceRevisionId":"Q137943996:content:5a5e50c7f7530613","sourceContentHash":"fnv1a64:b89af8d2cc6ecdc5","recordRevisionId":"Q137943996:content:5a5e50c7f7530613","recordContentHash":"fnv1a64:6b065d037c5ae9ac","sourceCanonicalUrl":"https://efferon.com/","sourceModifiedAt":"2026-10-24T19:00:45.503Z","observedOn":"2026-10-24","permission":{"basis":"public_information","evidenceUrl":"https://efferon.com/"},"attributionUrl":"https://efferon.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"Is Efferon NEO approved for use in children?","summary":"Cited source answers across 1 active corpus record.","question":"Is Efferon NEO approved for use in children?","answers":[{"entitySlug":"efferon-q137943996","entityName":"Efferon","answer":"“Yes. Efferon NEO received the CE MDR mark in April 2026 and is the first multimodal extracorporeal blood purification device specifically approved in Europe for pediatric patients with sepsis and septic shock from 1 month of age. In the multicenter LASSO NEO trial (NCT05707494) Efferon NEO significantly reduced 28-day mortality (9% versus 35% in controls).”","sourceUrls":["https://efferon.com/indications/"]}]}